Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( <scp>INTEGUMENT</scp> ‐ <scp>PED</scp> ): A Phase 3 Randomized Controlled Trial
Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( INTEGUMENT ‐ PED ): A Phase 3 Randomized Controlled Trial
Rocco Serrao, Tracy Funk, Robert Higham, Eric L. Simpson et al.
Citations
6 citations
Journal
Pediatric Dermatology
Topics
Dermatology and Skin Diseases
Field-Weighted Citation Impact (FWCI)
12.03
article
Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( INTEGUMENT ‐ PED ): A Phase 3 Randomized Controlled Trial
Rocco Serrao, Tracy Funk, Robert Higham, Eric L. Simpson, Scott Snyder, Patrick Burnett, Mark S. Lee, Mark Boguniewicz, Vimal H. Prajapati, Melissa S. Seal, Lawrence F. Eichenfield, Diane T. Hanna, Adelaide A. Hebert, Mercedes E. González, David H. Chu, David R. Berk, David Krupa, Lisa Swanson, Joseph Browning
article en
6 citations
Abstract
No abstract available for this paper.
Publication Tag
Pediatric DermatologyVol. 42(2)
Institutions
Oregon Health & Science University (US), University of Calgary (CA), National Jewish Health (US), University of California San Diego (US), Rady Children's Hospital-San Diego (US), Texas Dermatology and Laser Specialists (US), Probity Medical Research (CA), Progressive Clinical Research (US), Atara Biotherapeutics (United States) (US), The University of Texas Health Science Center at Houston (US), University of Colorado Denver (US)